Cargando…

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients

Detalles Bibliográficos
Autores principales:	Pandha, Hardev, Harrington, Kevin, Ralph, Christy, Melcher, Alan, Grose, Mark, Shafren, Darren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649281/ http://dx.doi.org/10.1186/2051-1426-3-S2-P341

Ejemplares similares

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Applications of coxsackievirus A21 in oncology
por: Bradley, Stephen, et al.
Publicado: (2014)

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
por: Müller, Louise M. E., et al.
Publicado: (2019)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
por: Yuan, Min, et al.
Publicado: (2015)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
por: Andtbacka, Robert HI, et al.
Publicado: (2015)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
por: Rudin, Charles M, et al.
Publicado: (2023)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy
por: Burnett, William J., et al.
Publicado: (2021)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome
por: Sam, Miranda, et al.
Publicado: (2023)

Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021)

Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18
por: Au, Gough G, et al.
Publicado: (2011)

Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
por: Liu, Huitao, et al.
Publicado: (2021)

SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus
por: Deng, James Z., et al.
Publicado: (2021)

2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus
por: Vorobyev, Pavel O., et al.
Publicado: (2022)

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
por: Jennings, Victoria A., et al.
Publicado: (2019)

Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients
por: West, Emma J., et al.
Publicado: (2022)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
por: Khushalani, Nikhil I., et al.
Publicado: (2023)

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo
por: Anesti, Anna-Maria, et al.
Publicado: (2010)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015)

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
por: Okamura, Koji, et al.
Publicado: (2022)

Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H
por: Hazini, Ahmet, et al.
Publicado: (2021)

Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
por: Liu, Huitao, et al.
Publicado: (2022)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming
por: Steele, Lynette, et al.
Publicado: (2011)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Differential effects of Paclitaxel on dendritic cell function
por: John, Justin, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e4hqeo5mp2jpi4tc44hi9ihogl